| Followers | 0 |
| Posts | 112 |
| Boards Moderated | 0 |
| Alias Born | 02/19/2019 |
Saturday, April 20, 2019 10:33:49 PM
Thank you for your outstanding input how did you feel about issue 2?
Recent ATOS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 11:22:50 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/30/2026 09:33:51 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 09:30:46 PM
- Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/25/2026 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2026 09:21:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:20:21 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 08:52:24 PM
- The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology • GlobeNewswire Inc. • 03/19/2026 03:00:00 PM
- Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives • PR Newswire (US) • 03/19/2026 12:00:00 PM
- Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference • PR Newswire (US) • 03/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:22:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/20/2026 09:16:05 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/20/2026 09:07:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 09:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 01:45:24 PM
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook • PR Newswire (US) • 02/11/2026 01:30:00 PM
- Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program • PR Newswire (US) • 02/05/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2026 01:00:26 PM
- Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy • PR Newswire (US) • 01/16/2026 09:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2026 01:15:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:30:24 PM
- Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer • PR Newswire (US) • 01/06/2026 01:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/22/2025 01:30:27 PM
- Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category • PR Newswire (US) • 12/17/2025 01:15:00 PM
- Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium • PR Newswire (US) • 12/15/2025 01:00:00 PM
